20034-50-8

Usage

Uses

Used in Pharmaceutical Industry:
4-Cyclopropylbenzaldehyde is used as a building block in the synthesis of pharmaceuticals for its unique chemical structure, which can contribute to the development of new drugs with novel therapeutic properties.
Used in Fragrance Industry:
4-Cyclopropylbenzaldehyde is used as a key component in the creation of fragrances, capitalizing on its strong, aromatic odor to enhance the scent profiles of various perfumes and scented products.
Used in Organic Compounds Synthesis:
4-Cyclopropylbenzaldehyde serves as a valuable intermediate in the synthesis of other organic compounds, leveraging its reactive aldehyde group and cyclopropyl ring for the production of a wide range of chemical products.

Upstream product

• 50-00-0 formaldehyd 
• 873-49-4 cyclopropylbenzene 
• 1124-14-7 1-bromo-4-cyclopropylbenzene 
• 68-12-2 N,N-dimethyl-formamide 
• 4885-02-3 Dichloromethyl methyl ether 
• 1122-91-4 4-bromo-benzaldehyde 
• 411235-57-9 cyclopropylboronic acid 
• 104-88-1 4-chlorobenzaldehyde 
• 925430-09-7 tricyclopropylbismuthane 
• 201230-82-2 carbon monoxide 
• 15164-44-0 p-(iodophenyl)carboxaldehyde 
• 3002-94-6 cyclopropyllithium 
• 192436-83-2 4-bromo-N-methoxy-N-methylbenzamide 
• 26979-32-8 7-Cyclopropylcycloheptatrien 

Downstream Products

• 1798-82-9 4-cyclopropylbenzoic acid 
• 109088-61-1 <(triisopropylphenyl)sulfonyl>hydrazone of p-cyclopropylbenzaldehyde 
• 115906-11-1 diethyl 2-(4-cyclopropylbenzylidene)malonate 
• 960384-01-4 2-(4-cyclopropylphenyl)-3-[2-(4-methoxyphenyl)ethyl]-4-oxo-1,3,8-triaza-spiro[4.5]decane-8-carboxylic acid tert-butyl ester 
• 115906-18-8 3-(4-Cyclopropyl-phenyl)-pyrrolidine-2,5-dione 
• 115906-12-2 2-(4-Cyclopropyl-phenyl)-succinic acid 
• 109088-45-1 1-Cyclopropyl-4-(2,2-dimethyl-3-methylene-cyclopropyl)-benzene 
• 109088-59-7 1-Cyclopropyl-4-diazomethyl-benzene 
• 454678-87-6 4-cyclopropyl-benzenemethanol 
• 875109-29-8 2-benzyloxyphenyl-(4-cyclopropylphenyl)methanol 
• 101557-96-4 1-(4-cyclopropylphenyl)pentan-1-one 
• 875109-31-2 1-benzyloxy-2-(4-cyclopropylbenzyl)benzene 
• 875109-33-4 2-(4-cyclopropylbenzyl)phenol 
• 545393-80-4 (2E)-3-(4-cyclopropylphenyl)prop-2-enoic acid 

Relevant academic research and scientific papers

Gold Catalysts Can Generate Nitrone Intermediates from a Nitrosoarene/Alkene Mixture, Enabling Two Distinct Catalytic Reactions: A Nitroso-Activated Cycloheptatriene/Benzylidene Rearrangement

Gold-catalyzed reactions of cycloheptatrienes with nitrosoarenes yield nitrone derivatives efficiently. This reaction sequence enables us to develop gold-catalyzed aerobic oxidations of cycloheptatrienes to afford benzaldehyde derivatives using CuCl and nitrosoarenes as co-catalysts (10-30 mol %). Our density functional theory calculations support a novel nitroso-activated rearrangement, tropylium → benzylidene. With the same nitrosoarenes, we developed their gold-catalyzed [2 + 2 + 1]-annulations between nitrosobenzene and two enol ethers to yield 5-alkoxyisoxazolidines using 1,4-cyclohexadienes as hydrogen donors.

Synthesis of Substituted Benzaldehydes via a Two-Step, One-Pot Reduction/Cross-Coupling Procedure

The synthesis of functionalized (benz)aldehydes, via a two-step, one-pot procedure, is presented. The method employs a stable aluminum hemiaminal as a tetrahedral intermediate, protecting a latent aldehyde, making it suitable for subsequent cross-coupling with (strong nucleophilic) organometallic reagents, leading to a variety of alkyl and aryl substituted benzaldehydes. This very fast methodology also facilitates the effective synthesis of a 11C radiolabeled aldehyde. Aluminum-ate complexes enable transmetalation of alkyl fragments onto palladium and subsequent cross-coupling.

Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952

Optimization of novel azetidine compounds, which we had found as colony stimulating factor-1 receptor (CSF-1R) Type II inhibitors, provided JTE-952 as a clinical candidate with high cellular activity (IC50 = 20 nM) and good pharmacokinetics pro

COMPOUNDS AND METHOD OF USE

This present disclosure relates to compounds with ferroptosis inducing activity, a method of treating a subject with cancer with the compounds, and combination treatments with a second therapeutic agent.

Palladium-Catalyzed Carbonylative Cross-Coupling Reaction between Aryl(Heteroaryl) Iodides and Tricyclopropylbismuth: Expedient Access to Aryl Cyclopropylketones

The carbonylative cross-coupling reaction between aryl and heteroaryl iodides and tricyclopropylbismuth is reported. The reaction is catalyzed by (SIPr)Pd(allyl)Cl, a NHC-palladium(II) catalyst, operates under 1 atm of carbon monoxide and tolerates a wide range of functional groups. The use of lithium chloride was found to provide higher yields of the desired aryl cyclopropylketones. The conditions were also applied to the carbonylative cross-coupling of an iodoalkene to afford the corresponding alkenyl cyclopropylketone.

COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT

Compounds and compositions useful for treating disorders related to Kit are described herein.

PIPERIDINE-DIONE DERIVATIVES

The invention provides novel compounds having the general formula (I) and tautomers and pharmaceutically acceptable salts thereof, wherein A1, A2, A3, A4, R1, R4, R5, R6, R7 and R8 are as defined herein, compositions including the compounds and methods of using the compounds.

SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS

The present disclosure is directed to substituted pyrimidine compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and a

IMIDAZOTRIAZINONE COMPOUNDS

The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.

AZETIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF

Compounds of formula [I]: wherein each symbol is as defined in the description, or a pharmaceutically acceptable salts or solvates thereof.